Health and Me on MSN19h
If You’ve Never Smoked, Why Are You At Risk For Lung Cancer?
Dust, smoke, and chemicals in the air cause about 1%-2% of lung cancers. Researchers suspect that polluted air can cause ...
pharmaphorum10h
Kelun-Biotech first to bag TROP2 approval in lung cancer
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...
Fierce Pharma3d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Scaling Liquid Biopsies And Cancer Diagnostics: The EASY Way
While liquid biopsies can offer significant advantages, there are critical factors to assess the quality of these solutions ...
Targeted Oncology1d
Exploring Targeted Treatments and Their AEs in EGFR-Mutated NSCLC
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March ...
GlobalData on MSN2d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
PMLive6d
J&J’s Lazcluze/Rybrevant combination granted MHRA approval for lung cancer
Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...
Nasopharyngeal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Nasopharyngeal Cancer Companies are involved in targeted therapeutics development with respective active and inactive ...
Hoth Therapeutics, Inc.: Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor ...